We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,900 Open access books available
116,000 International authors and editors
120M Downloads

154 Countries delivered to
TOP 1% Our authors are among the most cited scientists
12.2% Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Chapter 4

Olfaction, among the First Senses to Develop and Decline

Emanuele Brai and Lavinia Alberi

Abstract

Olfaction is one of the most conserved senses across species. It plays a crucial role in animals’ and humans’ life by influencing food intake, reproduction and social behavior. The olfactory system is composed of a peripheral neuroepithelium and a central olfactory nerve and is one of the few central nervous system (CNS) structures with direct access to the external environment without passage through the Blood Brain Barrier (BBB). This makes this nerve system of importance for understanding how exogenous stimuli may contribute to neuronal damage as well as for diagnostic and therapeutic purposes. Interestingly, olfactory activity physiologically declines with aging, but its alteration can be further impaired by various neurological conditions. For example, in progressive neurodegenerative disorders, such as Alzheimer’s disease (AD), olfaction is the first sense to be impaired before the onset of cognitive symptoms, suggesting that olfactory transmission may characterize early neural network imbalances. In this work, we will explore the main olfactory anatomical structures, the cytoarchitecture, the neurogenesis, several pathological conditions characterized by olfactory deficit and the potential use of this sense to diagnose and treat CNS pathologies.

Keywords: olfaction, olfactory system, olfactory dysfunction, Alzheimer’s disease, chronic inflammation, cancer, traumatic brain injury, neurological disorders, olfactory tests, nasal biopsies, diagnosis, therapeutic target

1. Introduction

Olfaction is among the most preserved senses across species based on its fundamental role for survival. In fact, this sense influences vital activities such as feeding, reproductive and social behavior.
The variety of functions modulated by olfaction relies on the direct connectivity of the olfactory tract to the piriform cortex, entorhinal cortex, hippocampus and amygdala regulating innate and acquired olfactory perception, memory, fear and alertness (Figure 1). In mammals, the major components of the olfactory system consist of the olfactory neuroepithelium (OE), the primary olfactory area, the olfactory bulb (OB) and its cortical projections, considered as secondary olfactory network areas (Figure 1) [1]. The olfactory network is, besides the visual system, the only nerve tract with direct access to the external environment without passage through the BBB and represents a viable and non-invasive source of CNS-derived biomarkers. Furthermore, chemosensory transduction manifests itself through the sense of smell, which is readily testable [2]. The olfactory system starts developing at mid gestation [3–5] and is mainly unchanged in all vertebrates [6, 7]. After birth, olfaction is essential in assisting the development of locomotor activities and spatial orientation as demonstrated in both rodents and humans [8–11]. These evidences underlie how the onset of olfactory deficits may induce a wide range of (reversible or irreversible) impairments with potential life-threatening consequences. The most common alterations consist in either an exaggerated sense of smell “hyperosmia,” a reduced sense of smell “hyposmia” or the absence of smell “anosmia”. Hyperosmia is often co-symptomatic to schizophrenia and manic disorders [12, 13], whereas hyposmia occurs naturally with aging [14] and is exacerbated in progressive neurodegenerative disorders, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) [14–17]. In addition, olfaction can be also completely

Figure 1. Olfactory system anatomy in the mammalian brain. Drawing of the primary (I) and secondary (II) network areas of the olfactory system and its corticofugal (continuous lines) and centrifugal (dotted lines) connections. The pseudostratified neuroepithelium located in the upper olfactory mucosa is displayed with its major cell types, epithelial cells (EC), globose basal cells (GBC), sustentacular cells (SUS), olfactory sensory neurons (OSNs). The OSNs project their apical dendritic cilia in the nasal cavity and their axons towards the brain to form the olfactory nerve layer (ONL, blue highlight), by passing through small foramina in the cribriform plate (CP). In the olfactory bulb, the ONL terminals synapse with excitatory mitral cells (MC; positive charge) and tufted cells (TC, not represented) in the glomerular layer (GL). Inhibitory periglomerular cells (PGCs; negative charge), dopaminergic PGCs (DA, positive charge) and inhibitory granular cells (GC, negative charge) modulate the activity of MC and TC through dendrodendritic synapses. MC axonal projections assemble to form the lateral olfactory tract (LOT, yellow highlight) projecting to the piriform cortex, entorhinal cortex, amygdala and hippocampus, representing the olfactory cortex (II). Cholinergic terminals (ACh, orange) from the horizontal limb of the diagonal band of Broca (HDB), serotoninergic efferents (5-HT, light blue) from the raphe nuclei, and noradrenergic fibers (NA, green) from the locus coeruleus innervate the olfactory bulb and olfactory cortex. Dopaminergic neurons of the ventral tegmental area (VTA, red) modulate the activity of the olfactory cortex. Cc: cortex.
lost after trauma [16, 18, 19] or certain types of cancer [20–23]. Furthermore, the early olfactory deficit in AD [24] has been shown to be a strong predictor of the progression of dementia [25–28]. Diagnosis of this sense remains underlooked and there is no consensus on the use of olfactory tests to assess/categorize neurological dysfunctions [29]. Interestingly, the studies testing olfaction in Tau and APP mouse models of AD, or α-synuclein models have shown that this sense is significantly altered [30–32]. Moreover, recent studies raise the possibility that endogenous [33–37] (PrP, Aβ, Tau, α-synuclein) and microbial [38, 39] amyloid-like peptides are accumulated in the nasal neuroepithelium and may propagate via retrograde transport to higher brain structures [40]. This might explain why Aβ, Tau, α-synuclein depositions are first observable in the olfactory bulb and olfactory tract, as their accumulation is associated to fibrillary tangle dysgenesis [41] and correlate with Braak staging progression [42].

Despite the strong evidence indicating that olfactory transmission deficit is an early predictor of neurodegenerative processes, the poor understanding of the molecular and cellular mechanisms underlying olfactory activity in the primary as well as secondary olfactory network areas has marred the use of olfaction and olfactory testing as bona fide targets in clinical setting. In this chapter, we elaborate on the anatomical and physiological properties of the olfactory system, its development by sampling the vast literature of olfaction in mammals. We then expand on the role of olfaction in humans and smell deficits as readout of neurological diseases as well as other pathologies. With this work we aim to provide further support for considering the olfactory system as source of physiological and biological biomarker(s) based on its direct connection with the brain and emphasize the use of this easily accessible sensory system as an ideally suited functio-anatomical window for monitoring brain health as well as for therapeutic targeting.

2. Olfactory system anatomy

In vertebrates the olfactory network is activated when an odorant, inhaled through the airways, binds to a specific receptor expressed on specialized neurons, known as olfactory sensory neurons (OSNs) or olfactory receptor neurons (ORNs), embedded in the upper olfactory mucosa. Every OSN expresses a specific odorant receptor (OR), which is activated only when a unique ligand (odor molecule) binds to it [43]. In 1991, Buck and Axel identified 18 genes encoding ORs [44] and for such discovery they were awarded the Nobel Prize in 2004. Few years later, more than 1000 OR genes were discovered in rodents [45] but only 378 OR were found in humans [46]. The OSN are characterized by their unique and exclusive ORs expression. The sorted olfactory signal is then transmitted from the OSNs’ axons, bundling as the olfactory nerve layer (ONL) in direction of specific glomeruli located in the OB [47]. Furthermore, innervation of the OB by the OSN axons is spatially segregated along the dorsomedial and lateroventral axis (zone I, II, III, and IV) respecting the spatial positioning of these neurons in the neuroepithelium. This “glomerular convergence” allows OSN projections to be widely dispersed across the bulb, while maintaining specificity for classes of odorant chemicals. For example, the dorsomedial zone I has convergence of OSN axons detecting n-fatty acids or n-aliphatic aldehydes but not alkanes [47–49]. The chemical and anatomical organization of ONL inputs defines the discrete odorant map of the OB, which is further relayed to the connecting mitral (MC) and tufted cells (TC) via axodendritic synapses [48]. Mitral and tufted principal neurons, constituting the output from
the OB to the cortex, are finely tuned through dendrodendritic synapses mostly from peri-
glomerular (PGC) and granular (GC) interneurons. These GABAergic and dopaminergic (DA)
neurons are continuously replaced at least in rodents [50–52] and are essential for modulating
mitral and tufted cells' firing rates and increasing/decreasing their synchronous firing activity
in presence/absence of an odorant [53–55]. Further, cholinergic, serotonergic and noradren-
ergic afferents, originating respectively from the horizontal limb of the diagonal band of Broca
(HDB) [56], raphe nuclei [57] and locus coeruleus [58], modulate the response of the PGC, MC
and GC (Figure 1). These centrifugal afferents innervate the bulb in its integrity and appear to
be involved in the early deficit observed in AD and PD [59]. From the bulb, axonal projections
of the relay MC, form the lateral olfactory tract (LOT) and innervate higher brain areas (Figure
1). Neuroimaging studies reveal that the higher olfactory areas encompass different cerebral
structures, which are mainly divided in primary and secondary olfactory regions [60, 61]. The
first network area comprises the piriform and entorhinal cortices, the amygdala and hippocam-
pus, whereas the second neuronal hub includes the thalamus, the orbitofrontal cortex, cingulate
and insula [60, 62, 63]. In these higher brain areas, the signal is integrated and loses spatial
resolution [64]. This decomposition effect has been explained by the combinatorial cortical net-
work ideally suited for decoding of incoming spatially segregated signals [65]. Overall, based
on the heterogeneity of brain structures implicated in the modulation and processing of olfac-
tory stimuli, the olfactory deficit phenotype and the degree of severity of olfactory impairment
may vary substantially.

3. Adult neurogenesis in the olfactory system

In all mammals, including humans, neurogenesis is maintained in the neuroepithelium
through the presence of neural stem cells located close to the basal lamina. In adult rodents
two type of cells populate the stem cell niche, globose basal cells (GBC), representing the neu-
ral stem cells population and horizontal basal cells (HBC), with ependymal cell characteristics
functioning as supporting neurogenic cells. Conversely, in humans there is no distinction
between GBC and HBC, with the first appearing as the only population occupying the niche
[66]. GBCs comprise transit amplifying Mash1 positive progenitors and Ngn-1 expressing
Intermediate Neural Progenitors (INPs), ultimately differentiating into OSN [67, 68]. Besides
the neurogenic lineage, GBC give also rise to SUS, a glial-like cell type intercalated between
OSNs in the epithelium [69, 70] (Figure 1). The sustained regenerative capacity of the neuro-
epithelium can compensate for the vulnerability of the OSNs and SUSs, which are in direct
contact with the airways of the nasal cavity exposed to exogenous species, such as micro-
organisms and possible neurotoxic particles. The interaction between potentially dangerous
sources and the cells of the neuroepithelium requires a continuous cell turnover in order to
maintain the network functionality. Furthermore, the stem cells of the neuroepithelium repre-
sent a source of human neuronal precursors that may be employed for in-vitro pharmacology
studies, diagnostic and regenerative therapies [71, 72].

In rodents, neurogenesis takes place in the OB, where both GC and PGC are constantly
replaced via the migration of neuronal precursors from the lateral ventricles walls to the rostral
migratory stream (RMS), to reach their final destination areas: the periglomerular cell layer
and granule cell layer [73]. It has been long debated whether OB neurogenesis occurs also in humans. Despite the presence of glia cells in the adult human SVZ, potentially representing a quiescent stem cells’ population, doublecortin positive migrating neurons are observed in the RMS only until the 6th month of age postnatally [74]. Overall, the events promoting the renewal and replacement of the OB interneurons support the cellular turnover of the OB and its evoked odorant activity. This may have an essential role in the regulation of physiological functions in rodents, such as recognition of pheromones and food intake, or in favoring the distribution of infectious substances, entering into the brain via the nostrils and reaching the OE/OB compartment. On the other hand, the lack of OB neurogenesis in humans might be explained on one side by the reduction of olfactory diversity, since they present less turnover in the CNS networks compared to rodents, and by the compensatory use through other senses (vision, hearing, somatosensation, gustation) requiring less adaptive integration from the renewing interneurons.

4. Signaling transduction in olfaction

Olfactory transduction begins at the level of the cilia of the OSN protruding in the nasal cavity and through cascading amplification mechanisms reducing the threshold for odorant molecules detection. Each olfactory sensory neuron has about 12 ciliary branches, which increase the binding probability of the odorant molecules to the receptors compensating for the sequestration of the molecules in the nasal mucous covering the nasal neuroepithelium. Discrete odorants interact with specific olfactory receptors and activate a sequence of intracellular events leading to ionotropic channel activation and excitatory transmission through the ONL to the brain. In rodents, there are about 1000 genes encoding for different ORs. Each olfactory sensory neuron expresses only one type of OR through a monoallelic stochastic gene selection process occurring during the maturation of the OSN [43]. The ORs are G-protein coupled transmembrane receptors characterized by seven hydrophobic domains, whose diversity determines the heterogeneity and specificity of the response [75]. Upon binding to the odor molecule, a Gα olf protein, associated to the OR, is activated and converts guanosine 5’-diphosphate (GDP) to guanosine 5’-triphosphate (GTP). Further, by detachment of the beta/gamma subunits it activates the adenylate cyclase (AC) transmembrane protein converting ATP into a c-AMP [76]. This secondary messenger, c-AMP, has a high diffusion speed (20 μm/s) [77] and is rapidly sensed by the surrounding ionotropic Ca²⁺/Na⁺ gated channels (CNG) allowing Ca²⁺/Na⁺ inflow [78]. The rise in Ca²⁺ activates the Cl(Ca) channels, which extrude Cl-ions, potentiating by about 90% the depolarizing inward current [79, 80]. Intracellular ciliary Ca²⁺ influences the sensitivity of the CGN to c-AMP determining its desensitization or adaptation when exposure to an odor is prolonged or when the interval between exposures is short [81]. This mechanism needs to be taken into account when planning an olfactory testing paradigm in rodent and humans. Finally, unrelated odorants switch off CNG channels in a phenomenon called masking, which preserves the specificity of signal transduction to the OB [82]. These cascading events expand the signal transduction time from 1 millisecond to the order of 100 milliseconds [83] producing a molar non-linear amplification of the signal and contributing to the signal persistence. The excitatory signal from the ONL axons is then transferred to the apical dendrites of MC through glutamatergic synapses [84] and modulated through presynaptic and postsynaptic inputs of DAergic and GABAergic afferents of PGC and juxtaglomerular
interneurons spanning one or more glomeruli and regulating the spatiodynamic resolution of the odors evoked responses [85, 86]. Further, firing synchronization and signal amplification is achieved by dendrodendritic inhibitory synapses between GC and MC located in the external plexiform layer [87, 88]. The fine-tuned excitatory signal is relayed through the LOT to the cortical and neocortical structures, where an odor-evoked depression, by presynaptic metabotropic glutamate receptor (mGluR) II/III activation, contributes to signal adaptation and attenuation, typical of the cortical sensory responsiveness [89, 90]. Despite the physiology of olfactory transmission has been well characterized in rodents, much less is known about the physiology of this system in humans.

5. Olfaction in early life, adulthood, aging and mortality

Olfaction is among the most preserved senses throughout species and plays a vital role in daily life, being fundamental for feeding, reproductive and social behavior. Several studies described that in mammals, including humans, the sense of smell is developed during the first weeks of fetal life [9, 22, 91, 92]. Both in rats and humans, it has been shown that the odor of the amniotic fluid and the milk from the mother are perceived and memorized by the fetus, which, after birth, is capable to recognize and distinguish them from those of a surrogate mother [8, 10]. Moreover, experiments of olfactory stimulation in rat pups just after birth (0, 1, 2 hours) show an increase in locomotor activity compared to the unexposed pups [9].

In humans, clinical observations conducted on infants revealed their capability in locating the mother’s breast without assistance [93, 94], suggesting that the maternal breast odor is the driving force guiding their orientation and providing a sense of protection [9]. For instance, during hospitalization, the maternal contact and odor have a beneficial effect on relaxing the neonate when crying. These aspects constitute the “non-verbal communication”, which plays a fundamental role during the early neonatal phase to build and reinforce the mum-infant bonds [10]. Infants familiarize with odorants during pregnancy through mum’s diet, through a chemosensory transmission mother-infant [92]. Thus, in the critical period of early postnatal development, when vision is still poor, olfaction is employed as one of the first senses besides touch to make contact with the external world. Even if with adulthood, olfaction becomes less relevant for survival, particularly in modern humans, it underlies strong odor-cued memories and emotions. These associative processes triggered by odor perception depend on the output of the LOT to the hippocampus and amygdala and have been essential for animals to locate food [95], for the selection of mating candidates [96] and to identify predators [97, 98]. One of the most striking examples of olfactory sensitivity for foraging is the ability of the brown bear to sniff odors from more than 10 miles away, therefore representing a significant threat to campers and hikers carrying food in natural reserves. Studies indicate that the acuity and high sensitivity to odors of larger canid depends on the extended olfactory surface areas of the turbinates rather than the relative size of the olfactory system to the brain [99]. Furthermore, the smell-based mate selection is most prominent in females and appear to be dependent on the HLA variants inherited by the father [100, 101], triggering an emotional and behavioral response aimed at reproductive activity and species’ preservation. Finally, the “smell of danger” has been employed in odor-based fear conditioning to test amygdala’s function as well
as hippocampal plasticity [102, 103]. Interestingly, fox or cat urine is widely used in testing passive olfactory avoidance in rodents despite these laboratory animals never encountered a predator [104]. This suggests that odor-cued memories are ingrained in the DNA and research demonstrated that are the result of heritable epigenetic modifications [105]. Furthermore, studies in humans showed that most odor-cued memories are formed in the first decade of life [106] and appear stronger than the ones evoked by words or visual cues reflecting accurately one’s autobiography throughout life [107, 108]. Finally, olfactory acuity is particularly developed in occupational workers such as sommeliers, perfumers and chefs, which can perceive hedonic odors among a mix to deliver unique pleasant and palatable combinations [109, 110]. It remains unclear whether odor protheticity depends on the plasticity of the neuroepithelium or the distribution of the olfactory receptive elements. With aging, humans of both genders progressively lose their olfactory acuity and the ability to identify an odor: more than 50% of individuals aged 65–82 suffer from olfactory deficit [14, 111, 112]. Several factors account for the dysfunction including chronic damage to the neuroepithelium by neurotoxins and misfolded proteins [113], depletion of ciliary ORs, neuroinflammation and reduced vascularization [114]. As a result of the OSN damage with age, bulbar atrophy [115] and glomerular degeneration are associated to neurofibrillary tangle (NFT) depositions and olfactory processing and perception deficits [117]. Olfactory dysfunction (OD) in the elderly represents a source of discomfort and can pose a serious risk to safety [118]. Last, olfactory deficit has been shown to be an early predictor of mortality in old age [119]. This body of data indicates that olfaction is one of the primary form of environmental communication in mammals [120].

6. Olfactory dysfunctions

The olfactory activity is mainly composed of two hierarchical independent processes, where the first, defined as “peripheral”, is based on the acuity or capability to perceive an odorant, while the second, named as “central”, is involved in the memory or ability to identify an odor [61, 121]. Alteration in peripheral processes is linked to deficits occurring at the olfactory neuroepithelium, specifically at the levels of the OSN. On the other hand, damages to central processes can be attributed to deficits in the OB compartment and in higher cerebral regions, such as cortical and limbic system structures. This observation is supported by studies showing impaired odor identification with unaffected threshold activity in subjects presenting injuries in the orbitofrontal cortex or the dorsomedial thalamic nucleus [122]. The integrity of olfactory perception, normosmia, can be impaired by alterations which can be divided in two main categories indicating a (1) quantitative or (2) qualitative impairment of the sense of smell. The first category is composed by anosmia, hyposmia or microsmia and hyperosmia, whereas the second one is represented by dysosmia, subdivided in parosmia and phantosmia or olfactory hallucination. These categories and their definition are summarized in Table 1. Apart from normosmia, which represents the physiological condition of the sense of smell, all the other cases can be determined by a wide spectrum of causes. In order to assess olfaction in humans, several tests are nowadays available to monitor the sensitivity of the olfactory system aiming to detect at an early stage the presence of different disorders. A test, which is commonly adopted to evaluate the olfactory responsiveness, is the University of Pennsylvania Smell Identification Test (UPSIT), developed by Doty and colleagues in 1984 [29]. This scratch
Physiological olfactory condition

Normosmia: normal olfactory function

Quantitative olfactory dysfunctions

Anosmia: total loss of smell

Hyposmia: decreased sense of smell

Hyperosmia: increased sense of smell

Qualitative olfactory dysfunctions

Dysosmia: qualitative alteration of the sense of smell. It includes:
(1) Parosmia: odor distortion
(2) Phantosmia: odor perception without the presence of the source

and smell test enables the evaluation of the general smell function, e.g. odor identification and odor detection, assigning a final score which reflects the individual ability to recognize by exclusion several odors. The original tests includes 40 booklets with 4 odor per booklet, although shorter mini-UPSIT (Brief Smell Identification Test – BSIT) of 12, 15 and 16 odors

Table 1. Classification of the olfactory conditions.

<table>
<thead>
<tr>
<th>Physiological olfactory condition</th>
<th>Quantitative olfactory dysfunctions</th>
<th>Qualitative olfactory dysfunctions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normosmia: normal olfactory function</td>
<td>Anosmia: total loss of smell</td>
<td>Dysosmia: qualitative alteration of the sense of smell. It includes:</td>
</tr>
<tr>
<td>Hyposmia: decreased sense of smell</td>
<td>Hyperosmia: increased sense of smell</td>
<td>(1) Parosmia: odor distortion</td>
</tr>
<tr>
<td>Phantosmia: odor perception without the presence of the source</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 2. Breakdown of affected regions and potential mechanisms in olfactory deficiencies and window for diagnostic/treatment. Related processes, diseases and possible therapeutic approaches centered on the olfactory neuroepithelium (A), olfactory bulb (B) and olfactory cortex (C). Abbreviations: EC, epithelial cells; GBC, globose basal cells; SUS, sustentacular cells; OSN, olfactory sensory neuron; GC, granule cell; PGC, periglomerular cell; PGC (DA), periglomerular dopaminergic cells; ONL, olfactory nerve layer; CP, cribriform plate; GL, glomerular layer; MC, mitral cell; LOT, lateral olfactory tract; ACh, acetylcholine; DA, dopamine; 5-HT, 5-hydroxytryptamine; NA, noradrenaline; NFT, neurofibrillary tangles; AD, Alzheimer’s disease; PD, Parkinson’s disease; HD, Huntington’s disease; ALS, Amytrophic lateral sclerosis; ASD, autistic spectrum disorders.
have been used before [123–125] and they seem to be a viable solution for testing olfaction on human subjects limiting desensitization mechanisms intrinsic to olfactory transduction. On the other hand, a “forced-choice phenyl ethyl alcohol odor detection threshold test” [26], also called as the Snap and Sniff® Threshold Test, allows for rapid and reliable determinations of olfactory detection thresholds. Subjects are exposed to concentrations of phenyl ethyl alcohol, ranging from $10^{-2}$ to $10^{-9}$ log vol/vol in half-log concentration steps, along with blanks for forced-choice testing [126]. This test controls for a subject’s response bias or criterion for responding independently of the subject’s actual sensory sensitivity. Both tests can be self-administered and are equipped with a score card making olfactory testing accessible and convenient for both clinical and personal use.

Hereafter, we describe some human pathologies which can lead to olfactory dysfunctions (Figure 2).

### 7. Systemic diseases

#### 7.1. Chronic inflammation

Many pathological events are characterized by a persistent inflammatory response, as observed in patients suffering from sinonasal diseases, such as acute or chronic rhinosinusitis, allergic or non-allergic rhinitis [127–129] (Table 2). In addition to nasal congestion and altered mucus secretion, these conditions represent a common cause of olfactory impairment [127, 128, 130–132]. For instance, it has been reported that between 14 and 30% of the patients affected by chronic rhinosinusitis (CRS) show olfactory dysfunction [129, 132–134]. The inflammatory event underlying sinonasal pathologies can be divided in two processes: the inflammatory mechanism itself and the conductive (or transport) component [127–129, 135], which compromises the proper diffusion of odorants towards the olfactory neuroepithelium [136–138]. The functionality of the nasal epithelium is affected since the topical inflammation reduces the airflow and subsequently the binding of the odor molecules to the ORs expressed on their cilia. The synthesis of pro-inflammatory factors can induce the loss or impairment of the ORs, which are then unable of signal transmission due to a reduced detection threshold [129, 135]. Several studies suggest that

<table>
<thead>
<tr>
<th>Pathology</th>
<th>Olfactory impairment</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic inflammation (Chronic Rhinosinusitis)</td>
<td>Anosmia, hyposmia</td>
<td>127–129, 133, 134</td>
</tr>
<tr>
<td>Cancer (Head–neck cancer)</td>
<td>Hyposmia, dysosmia</td>
<td>20, 146, 156, 157</td>
</tr>
<tr>
<td>Traumatic brain injury</td>
<td>Reversible anosmia, reversible hyposmia, reversible parosmia</td>
<td>19, 176–179, 184, 185</td>
</tr>
<tr>
<td>Neuropsychiatric disorders (Schizophrenia and ASD)</td>
<td>Hyposmia, hyperosmia, dysosmia</td>
<td>60, 61, 189–193, 196–198, 219, 220</td>
</tr>
<tr>
<td>Neurodegenerative diseases (Alzheimer’s, Parkinson’s and Huntington’s disease)</td>
<td>Hyposmia</td>
<td>17, 24–26, 226–228, 236–240</td>
</tr>
</tbody>
</table>

Table 2. Summary of the diseases described in this chapter and their observed olfactory alterations.
the relation between CRS and olfactory dysfunction could be multifactorial, since several events can trigger olfactory disbalance in chronic rhinosinusitis cases, such as the different degree of the inflammatory response [131, 132, 137] or the medical or surgical intervention in patients suffering from this pathology [129, 132]. Moreover, it has been described that CRS patients with anosmia present an altered mucus composition, which affects olfactory epithelium neurogenesis [139]. To evaluate and monitor the entity of olfactory loss in CRS subjects various tests can be carried out [140, 141] and also the detection of biomarkers, such as neuron-specific enolase [142] could provide further support in predicting the development of such disorder. All together, these evidence indicate that a constant inflammatory status of the nasal mucosa, in presence of rhinitis, sinusitis and rhinosinusitis can lead to a variable spectrum of olfactory dysfunctions whose severity depends from the inflammatory degree itself. The chronic inflammation in CRS and the absence of the BBB between the primary and secondary olfactory areas poses a serious risk for the propagation of neuroinflammatory species leading to neurodegenerative events. Indeed, a recent report indicates that patients with a history of chronic sinusitis are more prone to develop dementia [143] or stroke [144, 145]. This supports the notion that peripheral sinus inflammation should be promptly treated with pharmacological and surgical approaches, to contain the symptoms of nasal obstruction and prevent the neuroinflammatory spread.

7.2. Cancer

Studies on head and neck cancer (HNC) reported that different symptoms associated to the treatment, such as radiotherapy and chemotherapy, can include smell and taste dysfunction [20] (Table 2). The impairment in these senses can appear early in HNC patients and progressively become more severe in the long-term period [146]. Laryngeal cancer patients which are best treated by total laryngectomy, based on removal of the nasal neuroepithelium, suffer from hyposmia and gustatory alteration [21, 147]. In normal conditions the olfactory receptors are not considered as potential contributors in cancerogenesis, but their physiological capability in binding to organic compounds and the subsequent signal transduction essential for survival or migratory events could support their involvement in fostering cancer cells [148–150]. Interestingly, it has been described that some ORs are present in other tissues and organs not related to the “olfactory circuit”, such as muscle [151], kidney [152] and lung [22]. Former studies demonstrated that one OR is implicated in the pathobiology of prostate cancer cell migration and proliferation, making this protein a possible parameter to monitor the patient’s clinical condition [150, 153, 154]. Recently, Ranzani and colleagues investigated the characteristics of olfactory receptors in cancer cell lineage and tumors. Interestingly, they found that several ORs are expressed in different tumorogenic cell lines and tumors, e.g. the OR2C3 has been observed both in diverse cancer lines and melanomas, suggesting that this receptor might participate to the development of this tumor [23, 155]. Numerous studies showed that more than 70% of cancer cases show taste and smell dysfunctions [156]. Most of these alterations are reported after cancer treatment [157], whereas changes in these senses in pre-treatment phase are not clarified. The reasons could be attributed to multiple events, like (1) mechanical interference, due to tumor obstruction of the chemoreceptor sites; (2) neurological origin, where cancer affects signal transmission; and (3) metabolic, related to a higher urea concentration in the saliva associated to tissue catabolism [23, 158].

Another fundamental aspect which connects cancer and olfaction is the employment of this sense in early detection of this pathology. In particular, canine olfaction and lately electronic
noses (e-noses) represent a promising, non-invasive manner to screen tumors [159–161]. The high sensitivity of dogs in odorants perception render them suitable for this clinical purpose, in fact they are used to distinguish healthy controls and cancer subjects upon exposure of biological samples, whereas the electronic noses present chemo-sensory components able to identify specific biomarkers in exhaled breath [161]. Both canines and e-noses can detect volatile organic compounds (VOCs) in biological specimens. It is well recognized that dogs can perceive specific VOCs in several samples, such as urine, expired breath, blood and stool [162–166]. For instance, diverse VOCs have been identified in the breath of individuals affected by lung, ovarian, prostate, bladder and colorectal tumor [167–170]. The use of electronic noses is increasing as differently from dogs, do not require training and maintenance, are relatively inexpensive and easy to handle. These new devices can analyze volatile molecules present in expired air via gas chromatography and chemosensory apparatus [171–175]. Notably, both canine olfaction and e-noses represent two powerful systems in detecting several kinds of tumors during their asymptomatic stages allowing an earlier and potentially more effective therapy. Overall, it appears that olfactory deficits are involved in the clinical phase of cancer progression, and atypical odor identification can be employed to diagnose mutagenic processes early on.

8. Central nervous system disorders

8.1. Trauma

Traumatic brain injury (TBI) constitutes one of most frequent causes of olfactory dysfunction, affecting both genders [19, 176–178] (Table 2). One of the first medical reports about OD, in 1864, described a post-traumatic total loss of smell and a more dated description of anosmia was reported in 1837 after head trauma (HT) from a horse riding accident [179]. Depending on the severity of the trauma, the degree of olfactory impairment can show a quite diverse clinical outcome ranging from microsmia to anosmia [178, 180–182], which can be in both cases partially recovered [181, 182]. Subjects affected by parosmia show a gradual recovery of olfactory ability following a medium-long term period after the accident [178, 181]. The severity of the trauma depends also from the cranial region interested, i.e. frontal injury is associated with a lower olfactory disability compared to the temporal and occipital lobes [181], although there is contradictory evidence on the latter [179]. After head injury, MRI analysis revealed a reduction in olfactory bulb volume as compared to control subjects [178, 181]. The reason why after HT the sense of smell is often permanently lost is due to the failed regeneration of the olfactory neuroepithelium, which directly impacts the signal transmission to the OB. In particular, the axonal re-growth of the OSNs is influenced by the injury degree [183], since it can severely compromise the ONL over its whole length [181]. A crucial aspect, which is widely debated, is the olfactory function recovery after a traumatic brain injury (TBI), which distinguishes the post-TBI hyposmia as mild, medium and severe [178]. Several studies indicate a proportional cause–effect event between trauma severity and olfactory impairment [184, 185], whereas other works suggest that the TBI entity is not directly correlated with the degree of olfactory dysfunction [179, 180]. The trauma can also have indirect consequences on the olfactory system performance, affecting cortical and subcortical areas, which are involved in the physiological olfactory responsiveness. In clinical trials, it has been observed that administration
of therapeutics, such as steroids, might improve the olfactory activity in trauma subjects [186–
188]. By favoring the re-absorption of the edema or removal of the hematoma in the affected
area, steroids can increase or restore the sense of smell [188]. Overall, these observations indi-
cate that hyposmia is one of the subtlest sensory changes after trauma, which may phenotypi-
cally signal regenerative processes in these patients.

8.2. Schizophrenia and autism

A substantial number of studies indicates a correlation between schizophrenia and olfactory
impairment (Table 2). There are several aspects of olfaction that can be assessed to character-
ize the schizophrenia-spectrum disorders (SSD). In particular, subjects affected by this neu-
ropsychiatric disease present alterations in performing correctly diverse olfactory tasks, such
as odor sensitivity, identification and discrimination, when exposed to different odorants [60, 61, 189–192]. Due to the disbalance in olfactory activity, it has been suggested to consider this
deficit as a parameter to identify SSD. Moreover, the negative symptoms which characterize
this illness have been related to the dysfunction in olfactory accuracy [193]. Nevertheless,
there are controversial reports describing an alteration in the sense of smell in schizophrenia-
associated disorders [190, 194] and others showing the absence of olfactory changes between
psychotic patients and healthy controls [193, 195, 196]. Starting from this discrepancy, Auster
and colleagues addressed whether the presence of olfactory deficits could represent a reliable
marker for subjects potentially susceptible to develop schizophrenia. They investigated this
aspect comparing the smell functionality in four different groups: (1) schizophrenic individu-
als, (2) persons with different mental disorders than schizophrenia, (3) subjects affected by
schizotypy and (4) healthy controls [193]. To achieve their goal, they modified a common
olfaction test, the “Sniffin’ Sticks” [193, 197], in order to expand its efficiency for free recall
tests in addition to olfaction ability and discrimination. They observed that schizophrenic
people appear to have a reduced assortment of pleasant odors compared to healthy subjects
and they report smells as less good over the controls [193, 196, 198], being in line with other
reports [66, 193, 196, 198, 199]. Functional and structural alterations of the olfactory circuitry
have been observed in schizophrenic patients using fMRI analysis [200] and electro olfacto-
gram (EOG) measuring olfactory evoked potentials (EP) [194, 201]. At the biomarker level,

---

Sensory Nervous System
excitatory neurons, it is conceivable that olfactory transmission defect can arise early on due to the interference of feedforward inhibition of PGC and GC onto mitral cells, necessary for olfactory signal sorting/scaling [207–209]. The connection between neurodevelopmental deficits, E/I imbalance and olfactory deficits in adult life is captured by the numerous studies indicating that the developmental molecule Reelin [210], regulating synaptic plasticity, behavior [211–213] and olfaction [30], is reduced in a subset of interneurons in the prefrontal cortex of schizophrenic patients [214]. Interestingly, Reelin deficiency has also been reported in AD [215–217], suggesting common mechanisms between schizophrenia and progressive neurodegeneration. E/I imbalance also alters dopaminergic transmission. In the setting of local and corticofugal dopaminergic innervation to the bulb, it is expected that olfactory signal transmission may be also affected, as previously demonstrated in rats treated with inhibitors of D2 receptor [218]. This body of studies supports the notion that olfactory impairment may be an early indicator of E/I imbalance.

Only recently the attention has been pointed on the possibility of olfactory deterioration in autism spectrum disorders (ASD), comprising autism (stricto sensu) and Asperger syndrome [219, 220] (Table 2). ASD individuals reported an unpleasant strong perception of odors and Galle and colleagues demonstrated that depending on the olfactory tasks performed, a difference in autistic, Asperger and control subjects could be recognized. In particular, the olfactory identification was affected in autistic individuals compared to the other groups [219]. Furthermore, studies using rodent models indicate the olfactory bulb among the brain regions critical for ASD pathogenesis [221–223]. Moreover, the OR2L13G-protein locus, initializing neuronal response to odorants, was shown to be differentially methylated in ASDs suggesting a possible rationale for olfactory dysfunction in these pathologies.

Developmental NMDA hypofunction is also reported in ASD [224, 225]. In both schizophrenia and ASD, E/I imbalances at bulbar and cortical level likely underlie the olfactory transmission alterations.

8.3. Progressive neurodegenerative disorders

Olfactory activity progressively decreases with aging [14] and its decline is even accelerated with chronic neurodegenerative disorders, such as Alzheimer’s disease (AD) [25, 26], Parkinson’s disease (PD) [17, 24] and Huntington’s disease (HD) [226, 227] (Table 2). Olfactory dysfunction in PD is very prominent (90% of the cases) [228] and the extent of the impairment is comparable to the one observed in early onset AD and other progressive neurodegenerative disorders. Indeed, in the initial stages of AD the olfactory function is the first to be affected [24], so this sense could represent an early predictor of the disease. Olfactory dysfunction observed in progressive neurodegenerative diseases could underlie impairments in either the olfactory neuroepithelium, OBs, LOT or olfactory cortices [42]. Interestingly, it has been reported that proteinaceous aggregates, like Amyloid-β [33], phosphorylated Tau [34, 35, 229], α-synuclein [230, 231], which are characteristic of AD, PD and HD, are deposited in first instance in the olfactory mucosa where they are thought to exert a bactericidal action [232]. The aberrant accumulation of misfolded proteins can trigger several side effects, causing a transduction deficit and inflammatory responses attempting to reduce/avoid the microbial diffusion into the brain. Based on the absence of the BBB in
the olfactory tract, cells and misfolded proteins can be easily propagated within the brain and subsequently affect other olfactory system components, as olfactory cortices and connected areas (hippocampus and amygdala) [233]. All these cerebral structures and their related functions are damaged in AD, and to a lesser extent in normal aging [42]. Interestingly, OB and olfactory tract axonal atrophy has been already detected in MCI which might progressively evolve in AD [234]. In the initial Braak stages, the OB undergoes axonal atrophy [235] and in the majority of definite AD cases the olfactory impairment correlate with cortical AD pathology [236–240]. These observations implicate an early critical involvement of the olfactory system in neurodegenerative disorders.

Several molecular mechanisms contributing to AD pathobiology have been demonstrated to interfere with olfaction:

1. Amyloid-β, which is overexpressed in AD and contributes to the amyloidogenic pathway, has physiological functions, ranging from metal ion sequestration, synaptic plasticity modulation, and antimicrobial activity [33]. The amyloid peptide shares some aspects with a highly conserved antimicrobial proteins (AMPs) family [232]. Based on their ability to form oligomers and fibrils to surround harmful microbial agents, toxic substances and even aberrant cells, the AMPs produced by the OSNs represent the first and only defensive barrier of the CNS against pathogens. Furthermore, beside its endogenous production, Aβ may also have a microbial origin, aggravating the neurodegenerative process [39, 241]. The gastrointestinal (GI) compartment represents the principal source of the human microbiome and is tightly connected with the CNS through the GI tract-CNS axis, which interconnects these structures via immune system molecules, cytokines, hormones and nervous signals [39, 242–244]. Interestingly, the microorganisms residing in the GI tract can synthesize several peptides including lipopolysaccharides (LPS) and amyloids [241, 242, 245, 246]. These evidence indicate that a mutual benefit host-microbiome is also related to the production of these amyloid exudates within a “homeostatic range”, that, when disbalanced, could likely contribute to the etiology of chronic neurodegenerative diseases [247–250]. Therefore, the impairment observed in amyloid turnover and clearance during neurodegenerative pathologies could be attributed to the combination of “human Aβ burden” and the additional microbial Aβ peptides. This growing amyloid load in the OE and GI tract, can cause chronic inflammation which on the long run may affect BBB integrity and functionality [38, 39, 247, 251–253]. Overall, the deposition of insoluble Amyloid-β causes several side effects as (i) olfactory transduction deficit due to interference with OSN surface receptors, (ii) inflammatory responses attempting to reduce/prevent the microbial diffusion and (iii) seeding activity into the brain.

2. ApoE4 carriers have a higher incidence of olfactory deficit and are at risk for developing AD [254]. Moreover, ApoE4 blocks OE cultures neurite outgrowth in contrast to the trophic role of ApoE2 and ApoE3 [255].

3. Reports show SOD upregulation in OE and OB in AD patients compared to healthy controls [256] as well as an increase in oxidative response in AD neuroepithelium [255].

4. Along with network hyperactivity in the early stages of dementia, a reduction of calcium binding proteins has been observed in OSNs [257].
5. Imbalances in Acetylcholine (ACh) [258, 259], Dopamine (DA) [260–262], Serotonin (5-HT) [57, 263], and Norepinephrine (NA) [264] of the centrifugal afferents to the bulb or olfactory cortex affect olfactory transmission but can also influence microglia activation and neuro-inflammatory processes [265, 266].

6. Transient overexpression of hAPP impacts the glomeruli structure and axonal projections towards the corresponding target [267], which is partially rescued by switching off the synthesis of hAPP.

7. Dystrophic axon terminals favor amyloid deposition in AD and other disorders [116].

8. Progressive reduction in neuronal signaling components such as Reelin [268, 269] and Notch [270, 271] in AD may influence olfactory transmission as shown in rodent models [30, 272].

Despite the non-specificity of olfactory dysfunction in neurodegenerative diseases, this deficit is apparent in the pre-symptomatic phase [273, 274]. The underlying mechanisms are still poorly understood and only few studies have analyzed olfactory behavior in animal models of AD (Tg2576 [36], hTau [36]) and PD (PinkKO [275], α-Syn [276, 277], Bac Tg [278], VMAT2 [279]). Taken the susceptibility of the olfactory system to early molecular changes occurring in dementia, olfactory functions could be employed to predict/monitor the onset of the cognitive symptoms in AD as well its progression.

9. Olfactory route for diagnostic and therapeutics

The advantage of nasal biopsies in investigating specific olfactory disorders and also related neurodegenerative pathologies is still debated. Several studies suggest that this surgical procedure might not be specific enough to be routinely adopted in identifying primary events which anticipate neurodegenerative diseases [280]. Nevertheless, both the accessibility and heterogeneous cytoarchitecture of the olfactory neuroepithelium, make this specimen valuable for molecular diagnosis of neurological diseases [281]. Furthermore, the increasing precision and accuracy in obtaining nasal biopsies through laser surgery render this procedure safe, fast and with no major consequences, due to the constant neurogenesis occurring in the OE [282]. Nasal biopsies can be employed to detect aberrant misfolded proteins (Aβ, p-Tau, α-Syn, PrP, etc.), produced by the OSNs, reflecting early neural network imbalances in the asymptomatic phase of different neurological pathologies. Furthermore, the stem cells population residing in the olfactory mucosa is a relevant source of biological material for diagnosing genetic modification related to neurological diseases, performing in-vitro pharmacology assays and possibly regenerative therapies after trauma. Thus, nasal mucosa biopsies constitute a useful tool in recognizing susceptible subjects with early subclinical neurodegenerative processes and introduce them well in advance to therapeutics or new medical trials. Sampling of the mucosa has been previously employed in the diagnosis of genetic variants in schizophrenia [71] and as experimental tool to investigate mechanisms underlying a variety of neurological disorders (ranging from schizophrenia, ASD, Rett syndrome, bipolar disorders to...
Alzheimer’s disease) [71]. Finally, nasal secretions may be also a valuable liquid biopsy to perform longitudinal monitoring of pathological profiles in the progression of AD [283, 284]. Besides the accessibility of the olfactory system for diagnosing brain health, intranasal (IN) drug delivery offers great potential for brain targeting through by-passing the BBB [285]. IN delivery is currently approved for systemic drugs for a wide range of indications, including hormone replacement therapy, osteoporosis, migraine, prostate cancer, and influenza vaccine [286]. Approved CNS applications include IN administration of opioids for chronic cancer pain (fentanyl, buprenorphine and morphine) [287] based on their small molecular weight (200–400 Daltons) and their rapid onset. Repurposing of IN insulin, approved for Diabetes I, is being investigated for the treatment of Insulin hypometabolism in dementia [288]. So far, the clinical studies have demonstrated that IN insulin can revert the cognitive symptoms and reduce the amyloid load in both MCI [289] and early stage AD [290, 291] (https://clinicaltrials.gov/). Nevertheless, the little understanding of the absorbance mechanisms through the nasal route and the biodistribution variability based on nasal secretion and local inflammatory processes are slowing down the development of intranasal CNS drug. Recent preclinical studies in rodents have underlined the potential of IN administration for CNS diseases, as this route shows superior pharmacodynamics [292], allows up to 20 folds higher drug bioavailability [293] and rapid transport through the rostral migratory stream to limbic structures [294]. Nevertheless, more clinical studies are needed to develop IN applications that have prognostic and diagnostic value.

10. Conclusions

Olfaction is one of the most essential senses in mammals throughout life and appears to be a relevant readout for both peripheral and central neural processes. The research in the past 30 years has used mouse models to cast light on important cellular and molecular mechanisms governing odor specification in the olfactory neuroepithelium and olfactory bulb and signal encoding in the cerebral cortex. During the same period, a bulk of clinical studies reported a strong association between many neurological diseases and olfactory deficits, suggesting that olfactory activity can sentinel subtle changes in key brain areas connected to the olfactory system. Nevertheless, the processes underlying this quite ubiquitous phenotypical dysfunction are poorly understood. Indeed, despite the clinical evidence from patients, relevant clinical models of neurological diseases have been rarely tested to unravel the basis of olfactory alteration. We believe that this field needs to close the gap between bench-side and bed-side research to devise better diagnostic and therapeutic strategies, which can exploit the accessibility and non-invasiveness of this cranial nerve.

Acknowledgements

This work is supported by the Swiss National Fund Grant No. 163470.
Conflict of interests

The authors declare no conflict of interests.

Author details

Emanuele Brai¹ and Lavinia Alberi²,³*
*Address all correspondence to: lavinia.alberi@unifr.ch
1 Neuro-Bio Ltd, Culham Science Centre, Oxford, UK
2 Swiss Integrative Center for Human Health, Fribourg, Switzerland
3 Department of Medicine, University of Fribourg, Fribourg, Switzerland

References


[56] Záborszky L, Carlsen J, Brashear HR, Heimer L. Cholinergic and GABAergic afferents to the olfactory bulb in the rat with special emphasis on the projection neurons in the nucleus of the horizontal limb of the diagonal band. The Journal of Comparative Neurology. 1986;243:488-509


Lim DA, Alvarez-Buylla A. The adult ventricular-subventricular zone (V-SVZ) and olfactory bulb (OB) neurogenesis. Cold Spring Harbor Perspectives in Biology. 2016;8:a018820


[76] Bakalyar HA, Reed RR. Identification of a specialized adenylyl cyclase that may mediate odorant detection. Science. 1990;250:1403-1406


[128] Klimek L, Eggers G. Olfactory dysfunction in allergic rhinitis is related to nasal eosinophilic inflammation. The Journal of Allergy and Clinical Immunology. 1997;100:158-164


[195] Compton MT, Chien VH. No association between psychometrically-determined schizotypy and olfactory identification ability in first-degree relatives of patients with schizophrenia and non-psychiatric controls. Schizophrenia Research. 2008;100:216-223


[201] Turetsky BI, Hahn C-G, Arnold SE, Moberg PJ. Olfactory receptor neuron dysfunction in schizophrenia. Neuropsychopharmacology. 2009;34:767-774


[206] Nakazawa K, Jeevakumar V, Nakao K. Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia. NPJ Schizophrenia. 2017;3:7


[213] Imai H et al. Dorsal forebrain-specific deficiency of Reelin-Dab1 signal causes Behavioral abnormalities related to psychiatric disorders. Cerebral Cortex. 2017;27:3485-3501

[214] Guidotti A et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: A postmortem brain study. Archives of General Psychiatry. 2000;57:1061-1069


Moberg PJ, Doty RL. Olfactory function in Huntington’s disease patients and at-risk offspring. The International Journal of Neuroscience. 1997;89:133-139


Henkin RI, Velicu I. 30 Insulin receptors as well as insulin are present in saliva and nasal mucus. Journal of Investigative Medicine. 2006;54:S378


Reger MA et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008;70:440-448


